Profiling proteasome activity in tissue with fluorescent probes

Molecular Pharmaceutics

Volumn 4, Issue 5, 2007, Pages 739-748

  Berkers, Celia R ^a   Van Leeuwen, Fijs W B ^a,b   Groothuis, Tom A ^a   Peperzak, Victor ^a   Van Tilburg, Erica W ^a,c   Borst, Jannie ^a   Neefjes, Jacques J ^a   Ovaa, Huib ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Activity profiling; Confocal microscopy; Proteasome; Proteasome inhibitor; Ubiquitin; Vinylsulfone

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; EPOXOMICIN; FLUORESCENT DYE; PROTEASOME; PROTEASOME INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL LABELING; CELL LYSATE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; FLUORESCENT DYES; HUMANS; MICE; MOLECULAR STRUCTURE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SUBUNITS;

EID: 35548946122     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp0700256     Document Type: Article

References (31)

1. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V. J.; Elliott, P. J.; Adams, J.; Anderson, K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61, 3071-3076.
2. Richardson, P. G.; Mitsiades, C.; Hideshima, T.; Anderson, K. C. Bortezomib: Proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med. 2006, 57, 33-47.
3. Etlinger, J. D.; Goldberg, A. L. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 54-58.
4. Glickman, M. H.; Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol. Rev. 2002, 82, 373-428.
5. Concannon, C. G.; Koehler, B. F.; Reimertz, C.; Murphy, B. M.; Bonner, C.; Thurow, N.; Ward, M. W.; Villunger, A.; Strasser, A.; Kogel, D.; Prehn, J. H. Apoptosis induced by proteasome inhibition in cancer cells: Predominant role of the p53/PUMA pathway. Oncogene 2007, 26, 1681-1692.
6. Stohwasser, R.; Standera, S.; Peters, I.; Kloetzel, P. M.; Groettrup, M. Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: Reciprocally regulated tissue expression of interferon-γ-modulated proteasome subunits. Eur. J. Immunol. 1997, 27, 1182-1187.
7. Dahlmann, B.; Ruppert, T.; Kuehn, L.; Merforth, S.; Kloetzel, P. M. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J. Mol. Biol. 2000, 303, 643-653.
8. Dahlmann, B.; Ruppert, T.; Kloetzel, P. M.; Kuehn, L. Subtypes of 20S proteasomes from skeletal muscle. Biochimie 2001, 83, 295-299.
9. Elliott, P. J.; Soucy, T. A.; Pien, C. S.; Adams, J.; Lightcap, E. S. Assays for proteasome inhibition. Methods Mol. Med. 2003, 85, 163-172.
10. Lightcap, E. S.; McCormack, T. A.; Pien, C. S.; Chau, V.; Adams, J.; Elliott, P. J. Proteasome inhibition measurements: Clinical application. Clin. Chem. 2000, 46, 673-683.
11. Bogyo, M.; Shin, S.; McMaster, J. S.; Ploegh, H. L. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem. Biol. 1998, 5, 307-320.
12. Kessler, B. M.; Tortorella, D.; Altun, M.; Kisselev, A. F.; Fiebiger, E.; Hekking, B. G.; Ploegh, H. L.; Overkleeft, H. S. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic β-subunits. Chem. Biol. 2001, 8, 913-929.
13. Ovaa, H.; van Swieten, P. F.; Kessler, B. M.; Leeuwenburgh, M. A.; Fiebiger, E.; van den Nieuwendijk, A. M. C. H.; Galardy, P. J.; van der Marel, H. L.; Ploegh, H. L.; Overkleeft, H. S. Chemistry in living cells: Detection of active proteasomes by a two-step labeling strategy. Angew. Chem., Int. Ed. 2003, 42, 3626-3629.
14. Verdoes, M.; Florea, B. I.; Menendez-Benito, V.; Maynard, C. J.; Witte, M. D.; van der Linden, W. A.; van den Nieuwendijk, A. M.; Hofmann, T.; Berkers, C. R.; van Leeuwen, F. W.; Groothuis, T. A.; Leeuwenburgh, M. A.; Ovaa, H.; Neefjes, J. J.; Filippov, D. V.; van der Marel, G. A.; Dantuma, N. P.; Overkleeft, H. S. A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem. Biol. 2006, 13, 1217-1226.
15. Dantuma, N. P.; Lindsten, K.; Glas, R.; Jellne, M.; Masucci, M. G. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome- dependent proteolysis in living cells. Nat. Biotechnol. 2000, 18, 538-543.
16. Fiebiger, E.; Story, C.; Ploegh, H. L.; Tortorella, D. Visualization of the ER-to-cytosol dislocation reaction of a type I membrane protein. EMBO J. 2002, 21, 1041-1053.
17. Lindsten, K.; Menendez-Benito, V.; Masucci, M. G.; Dantuma, N. P. A transgenic mouse model of the ubiquitin/proteasome system. Nat. Biotechnol. 2003, 21, 897-902.
18. Luker, G. D.; Pica, C. M.; Song, J.; Luker, K. E.; Piwnica-Worms, D. Imaging 26S proteasome activity and inhibition in living mice. Nat. Med. 2003, 9, 969-973.
19. Berkers, C. R.; Verdoes, M.; Lichtman, E.; Fiebiger, E.; Kessler, B. M.; Anderson, K. C.; Ploegh, H. L.; Ovaa, H.; Galardy, P. J. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat. Methods 2005, 2, 357-362.
20. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; Ovaa, H.; Berkers, C.; Nicholson, B.; Chao, T. H.; Neuteboom, S. T.; Richardson, P.; Palladino, M. A.; Anderson, K. C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005, 8, 407-419.
21. Kraus, M.; Ruckrich, T.; Reich, M.; Gogel, J.; Beck, A.; Kammer, W.; Berkers, C. R.; Burg, D.; Overkleeft, H.; Ovaa, H.; Driessen, C. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 2007, 21, 84-92.
22. Murphy, M. P.; Smith, R. A. Drug delivery to mitochondria: The key to mitochondrial medicine. Adv. Drug Delivery Rev. 2000, 41, 235-250.
23. Reits, E. A.; Benham, A. M.; Plougastel, B.; Neefjes, J.; Trowsdale, J. Dynamics of proteasome distribution in living cells. EMBO J. 1997, 16, 6087-6094.
24. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
25. Kisselev, A. F.; Goldberg, A. L. Proteasome inhibitors: From research tools to drug candidates. Chem. Biol. 2001, 8, 739-758.
26. Palmer, J. T.; Rasnick, D.; Klaus, J. L.; Bromme, D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. 1995, 38, 3193-3196.
27. Riese, R. J.; Wolf, P. R.; Bromme, D.; Natkin, L. R.; Villadangos, J. A.; Ploegh, H. L.; Chapman, H. A. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996, 4, 357-366.
28. Meara, J. P.; Rich, D. H. Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors. J. Med. Chem. 1996, 39, 3357-3366.
29. Shi, G. P.; Munger, J. S.; Meara, J. P.; Rich, D. H.; Chapman, H. A. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J. Biol. Chem. 1992, 267, 7258-7262.
30. Meng, L.; Mohan, R.; Kwok, B. H.; Elofsson, M.; Sin, N.; Crews, C. M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 10403-10408.
31. Korbel, G. A.; Lalic, G.; Shair, M. D. Reaction microarrays: A method for rapidly determining the enantiomeric excess of thousands of samples. J. Am. Chem. Soc. 2001, 123, 361-362.